Navigation Links
Cancer predisposition from genetic variation shows strong gender bias
Date:9/21/2009

CINCINNATICancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

In addition, the research indicates that the risk for development of cancer in individuals harboring the gene variant can be further increased as a result of environmental exposure.

Peter Stambrook, PhD, a professor in the department of molecular genetics, biochemistry and microbiology, and colleagues report their findings this week in Proceedings of the National Academy of Sciences (PNAS). Co-authors include researchers from Wright State University and the Laboratory for Health Protection Research, National Institute of Public Health and the Environment, the Netherlands.

Stambrook says the gene CHEK2 is part of a DNA damage response pathway that can have an impact on whether or not cancers develop. A CHEK2 variant, CHEK2*1100delC, is associated with increased risk of cancer.

"Women who carry this particular gene variant are predisposed to developing breast or ovarian cancer," says Stambrook, "while men have a higher risk of developing prostate cancer."

Stambrook's team has produced a mouse model in which the CHEK2 gene was replaced by the variant and found that the overwhelming majority of mice that developed cancer were femaleabout 80 percent, as opposed to slightly more than 15 percent for males. This contrasts sharply with the incidence of cancer in wild-type mice (those with the normal CHEK2 gene), in which male and female mice developed cancer to about the same extent but at a much lower frequency.

Stambrook says his team will be exploring possible reasons behind the difference, looking at hormonal involvement and possible interactions between the gene variant and estrogen receptors or estrogen itself.

By using a known carcinogen, dimethyl benzanthracene, the researchers also determined that mice that harbor the variant are more susceptible to an environmental challenge than those that don't. The compound was administered orally to female mice.

"When they delivered the compound, the lifespan of the mice was reduced significantlythey developed breast cancer as well as other types of cancers," Stambrook says. "In addition, the mice that harbored this variant were more susceptiblein other words, they developed tumors more quickly than wild-type mice."

Stambrook says that by learning more about the signaling pathway of the CHEK2 gene, researchers can explore ways to "rescue" it and identify potential therapeutic targets.

"It's an interesting gene," says Stambrook, "and there are a lot of interesting directions that this finding will take us."


'/>"/>

Contact: Keith Herrell
keith.herrell@uc.edu
513-558-4559
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Head, Neck Cancer Treatment Often Not Completed
2. Researchers Propose Improved Cervical Cancer Screening
3. World Health Organization Launches New Attack on Lung Cancer
4. John Theurer Cancer Center and Leukemia & Lymphoma Society Highlight Upcoming Trends in Hematological Malignancies
5. News from Medialink and P&G: Procter & Gamble Partners with National Breast Cancer Foundation, Inc. to GIVE HOPE to Millions of Women Across the Country
6. Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
7. Surgeon Battling Own Cancer Developed New Treatment
8. New Chemo Regimen May Benefit Ovarian Cancer Patients
9. New Drug May Offer Hope to Some With Lung Cancer
10. Hormone Therapy May Make Lung Cancer More Likely
11. Mens Health Network, The Washington Redskins and GlaxoSmithKline Team Up for Septembers Prostate Cancer Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: